drugset / Trial / NCT00003563

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

NCT00003563

Phase 3 Completed 430 enrolled Pharmacyclics LLC.
RandomizedFactorialOpen-labelTreatment

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gadolinium texaphyrin may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation. It is not yet known whether giving gadolinium texaphyrin with radiation therapy is more effective than radiation therapy alone in treating brain metastases. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without gadolinium texaphyrin in treating patients who have brain metastases.

Timeline

Start
1998-08
Primary completion
2001-09
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject motexafin gadolinium Diagnostic / imaging agent 5 mg/kg Intravenous